A phase II study of intravenous DX-8951f (exatecan mesylate) administered daily for five days every three weeks to pediatric and young adult patients with Ewing's sarcoma (ES), primitive neuroectodermal tumor (PNET), or desmoplastic small round cell tumor (DSRCT)

Trial Profile

A phase II study of intravenous DX-8951f (exatecan mesylate) administered daily for five days every three weeks to pediatric and young adult patients with Ewing's sarcoma (ES), primitive neuroectodermal tumor (PNET), or desmoplastic small round cell tumor (DSRCT)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Exatecan (Primary)
  • Indications Ewing's sarcoma; Sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2012 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
    • 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top